Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
(Reuters) - Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, diges...